An ASNC Information Statement: Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis
Resource Type
Information Statements, Practice Points
Year Published
2022
Related Resources
ASNC Comments to CMS on 2026 Medicare Physician Fee Schedule Proposed Rule
ASNC_Comments-to-CMS-on_CY2026-MPFS-Proposed-Rule_1832_09-12-2025_FINAL
ASNC Comments to CMS on 2026 HOPPS Proposed Rule
ASNC-Comments-to-CMS-on-CY2026-HOPPS-Proposed Rule_09_11_2025_Final
Cases
PET Case: The Silent Infiltrator: Role of FDG-PET in a Challenging Case of Inflammatory Cardiomyopathy
Case summary: 45-year-old male with no significant past medical history presented with…
